A Phase I/IIa Safety Study of Subretinal Implantation of CPCB-RPE1 (Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Seeded on a Polymeric Substrate) in Subjects With Advanced, Dry Age-Related Macular Degeneration (AMD)

Trial Profile

A Phase I/IIa Safety Study of Subretinal Implantation of CPCB-RPE1 (Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Seeded on a Polymeric Substrate) in Subjects With Advanced, Dry Age-Related Macular Degeneration (AMD)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 May 2018

At a glance

  • Drugs CPCB-RPE1 (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions; First in man
  • Sponsors Regenerative Patch Technologies
  • Most Recent Events

    • 11 May 2018 Status changed from recruiting to active, no longer recruiting.
    • 05 Apr 2018 According to an USC Eye Institute media release, results (n=4) of this study were published in the Science Translational Medicine.
    • 05 Apr 2018 Results presented in an USC Eye Institute media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top